Publicaciones en colaboración con investigadores/as de Florida International University (11)

2022

  1. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

    JCO global oncology, Vol. 8, pp. e2200123

2020

  1. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

    Critical Reviews in Oncology/Hematology, Vol. 151

  2. Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))

    Critical Reviews in Oncology/Hematology

  3. Precision prevention and cancer interception: The new challenges of liquid biopsy

    Cancer Discovery, Vol. 10, Núm. 11, pp. 1635-1644

2019

  1. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

2018

  1. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment

    Seminars in Cancer Biology, Vol. 52, pp. 259-268

2017

  1. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

    Cancer Letters, Vol. 402, pp. 43-51

2016

  1. BRAF mutations in non-small cell lung cancer: Has finally Janus opened the door?

    Critical Reviews in Oncology/Hematology, Vol. 101, pp. 32-39

2014

  1. ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it

    Translational Lung Cancer Research, Vol. 3, Núm. 4, pp. 250-261

  2. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

    Cancer Treatment Reviews, Vol. 40, Núm. 8, pp. 990-1004

  3. The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

    Current Drug Targets, Vol. 15, Núm. 14, pp. 1284-1292